You are here: Industry Insights > Pfizer

News List

Pfizer gets EC approval for Daurismo to treat newly diagnosed acute myeloid leukaemia pharmaceutical-business-review
July 02, 2020
Pfizer has secured approval from the European Commission (EC) for its Daurismo (glasdegib) to treat certain adult patients with newly diagnosed acute myeloid leukaemia (AML).
US approves Bavencio for bladder cancer pharmatimes
July 02, 2020
EMD Serono, the biopharmaceutical business of Merck KGaA, and Pfizer announced that the US Food and Drug Administration (FDA) has expanded use of Bavencio (avelumab) to include maintenance treatment of patients ...
BioInvent, Pfizer Extend Immunotherapy Research Term contractpharma
July 02, 2020
Allows the companies to further identify and characterize new targets and antibodies leveraging BioInvent's F.I.R.S.T drug discovery platform.
Pfizer, BioNTech post positive data from study of COVID-19 vaccine candidate expresspharma
July 02, 2020
If studies are successful and mRNA-based vaccine candidate receives regulatory approval, companies expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021.
Pfizer links with SidekickHealth for digital health solution pharmatimes
July 01, 2020
Pfizer has linked with Nordic group SidekickHealth to launch a digital therapeutics platform designed to empower patients to take more control of their own health and boost wellbeing across Europe.
EMA to consider expanding use of Merck/Pfizer's Bavencio pharmatimes
June 23, 2020
The European Medicines Agency has validated for review Merck and Pfizer's application to market Bavencio (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC).
MSD/Pfizer's diabetes drug Steglatro hits goal in CV outcomes trial pharmatimes
June 22, 2020
MSD and Pfizer have unveiled data from the Phase III VERTIS CV cardiovascular (CV) outcomes trial which add further evidence on the safety of their diabetes drug Steglatro (ertugliflozin).
Merck and Pfizer’s SGLT2 inhibitor STEGLATRO meets primary endpoint in VERTIS CV trial pharmaceutical-business-review
June 18, 2020
Merck, known as MSD outside the United States and Canada, and Pfizer Inc., announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin) ...
Pfizer announces positive top-line results from JADE TEEN trial of abrocitinib in adolescents with moderate-to-severe atopic dermatitis pharmaceutical-business-review
June 17, 2020
Pfizer announced positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor.
Gavi to award $75 million to Serum Institute of India for introduction of the pneumonia vaccine in d expresspharma
June 05, 2020
Until now, the only two producers of the pneumonia vaccine have been Pfizer and GlaxoSmithKline (GSK).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page